Search results: Sage Journals

Open accessReview articleFirst published 2024

Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIs

Jietao Ma, Letian Huang, Chengbo Han

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2026

Comparison of Post-Resistance Treatment Outcomes in EGFR-Mutated NSCLC Patients Following Third-Generation EGFR-TKI Therapy: A Retrospective Cohort Study

Xinyue Li, Kaibo Ding, Dujiang Liu [...]

Technology in Cancer Research & Treatment

Open accessResearch articleFirst published 2025

Treatment options for EGFR mutation-positive NSCLC patients with leptomeningeal metastases after third-generation TKI resistance: a retrospective real-world study

Wenhua Yun, Ailing Liu, Junxu Wen [...]

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published August, 2026

Comparison of first and third generation EGFR-TKIs for the treatment of advanced non-small cell lung cancer: A real-world study

Maitri Shah, Kashvi Shah, Hetvi Dave [...]

Journal of Oncology Pharmacy Practice

Restricted accessReview articleFirst published July, 2017

Treatment in EGFR-mutated Non-small Cell Lung Cancer: How to Block the Receptor and overcome Resistance Mechanisms

Claudia Proto, Giuseppe Lo Russo, Giulia Corrao [...]

Tumori Journal

Free accessReview articleFirst published October, 2015

Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance

Alfredo Tartarone, Rosa Lerose

Therapeutic Advances in Respiratory Disease

Restricted accessReview articleFirst published October, 2021

EGFR tyrosine kinase inhibitors in non-small cell lung cancer: treatment paradigm,current evidence,and challenges

Arafat Tfayli, Razan Mohty

Tumori Journal

Restricted accessReview articleFirst published July, 2018

Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation

Meredith K Bollinger, Amanda S Agnew, Gerard P Mascara

Journal of Oncology Pharmacy Practice

Free accessReview articleFirst published March, 2017

Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications

Oscar Juan, Sanjay Popat

Therapeutic Advances in Medical Oncology

Open accessReview articleFirst published 2018

Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors

Vera Hirsh

Therapeutic Advances in Medical Oncology

Open accessReview articleFirst published 2024

Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIs

Jietao Ma, Letian Huang, Chengbo Han

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2026

Comparison of Post-Resistance Treatment Outcomes in EGFR-Mutated NSCLC Patients Following Third-Generation EGFR-TKI Therapy: A Retrospective Cohort Study

Xinyue Li, Kaibo Ding, Dujiang Liu [...]

Technology in Cancer Research & Treatment

Open accessResearch articleFirst published 2025

Treatment options for EGFR mutation-positive NSCLC patients with leptomeningeal metastases after third-generation TKI resistance: a retrospective real-world study

Wenhua Yun, Ailing Liu, Junxu Wen [...]

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published August, 2026

Comparison of first and third generation EGFR-TKIs for the treatment of advanced non-small cell lung cancer: A real-world study

Maitri Shah, Kashvi Shah, Hetvi Dave [...]

Journal of Oncology Pharmacy Practice

Restricted accessReview articleFirst published July, 2017

Treatment in EGFR-mutated Non-small Cell Lung Cancer: How to Block the Receptor and overcome Resistance Mechanisms

Claudia Proto, Giuseppe Lo Russo, Giulia Corrao [...]

Tumori Journal

Free accessReview articleFirst published October, 2015

Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance

Alfredo Tartarone, Rosa Lerose

Therapeutic Advances in Respiratory Disease

Restricted accessReview articleFirst published October, 2021

EGFR tyrosine kinase inhibitors in non-small cell lung cancer: treatment paradigm,current evidence,and challenges

Arafat Tfayli, Razan Mohty

Tumori Journal

Restricted accessReview articleFirst published July, 2018

Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation

Meredith K Bollinger, Amanda S Agnew, Gerard P Mascara

Journal of Oncology Pharmacy Practice

Free accessReview articleFirst published March, 2017

Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications

Oscar Juan, Sanjay Popat

Therapeutic Advances in Medical Oncology

Open accessReview articleFirst published 2018

Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors

Vera Hirsh

Therapeutic Advances in Medical Oncology